23757186|t|Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.
23757186|a|The prevalence of attention-deficit hyperactivity disorder (ADHD) in the USA is estimated at approximately 4-9% in children and 4% in adults. It is estimated that prescriptions for ADHD medications are written for more than 2.7 million children per year. In 2010, US poison centers reported 17,000 human exposures to ADHD medications, with 80% occurring in children <19 years old and 20% in adults. The drugs used for the treatment of ADHD are diverse but can be roughly separated into two groups: the stimulants such as amphetamine, methylphenidate, and modafinil; and the non-stimulants such as atomoxetine, guanfacine, and clonidine. This review focuses on mechanisms of toxicity after overdose with ADHD medications, clinical effects from overdose, and management. Amphetamine, dextroamphetamine, and methylphenidate act as substrates for the cellular monoamine transporter, especially the dopamine transporter (DAT) and less so the norepinephrine (NET) and serotonin transporter. The mechanism of toxicity is primarily related to excessive extracellular dopamine, norepinephrine, and serotonin. The primary clinical syndrome involves prominent neurological and cardiovascular effects, but secondary complications can involve renal, muscle, pulmonary, and gastrointestinal (GI) effects. In overdose, the patient may present with mydriasis, tremor, agitation, hyperreflexia, combative behavior, confusion, hallucinations, delirium, anxiety, paranoia, movement disorders, and seizures. The management of amphetamine, dextroamphetamine, and methylphenidate overdose is largely supportive, with a focus on interruption of the sympathomimetic syndrome with judicious use of benzodiazepines. In cases where agitation, delirium, and movement disorders are unresponsive to benzodiazepines, second-line therapies include antipsychotics such as ziprasidone or haloperidol, central alpha-adrenoreceptor agonists such as dexmedetomidine, or propofol. Modafinil is not US FDA approved for treatment of ADHD; however, it has been shown to improve ADHD signs and symptoms and has been used as an off-label pharmaceutical for this diagnosis in both adults and children. The mechanism of action of modafinil is complex and not fully understood. It is known to cause an increase in extracellular concentrations of dopamine, norepinephrine, and serotonin in the neocortex. Overdose with modafinil is generally of moderate severity, with reported ingestions of doses up to 8 g. The most common neurological effects include increased anxiety, agitation, headache, dizziness, insomnia, tremors, and dystonia. The management of modafinil overdose is largely supportive, with a focus on sedation, and control of dyskinesias and blood pressure. Atomoxetine is a selective presynaptic norepinephrine transporter inhibitor. The clinical presentation after overdose with atomoxetine has generally been mild. The primary effects have been drowsiness, agitation, hyperactivity, GI upset, tremor, hyperreflexia, tachycardia hypertension, and seizure. The management of atomoxetine overdose is largely supportive, with a focus on sedation, and control of dyskinesias and seizures. Clonidine is a synthetic imidazole derivative with both central and peripheral alpha-adrenergic agonist actions. The primary clinical syndrome involves prominent neurological and cardiovascular effects, with the most commonly reported features of depressed sensorium, bradycardia, and hypotension. While clonidine is an anti-hypertensive medication, a paradoxical hypertension may occur early with overdose. The clinical syndrome after overdose of guanfacine may be mixed depending on central or peripheral alpha-adrenoreceptor effects. Initial clinical effects may be drowsiness, lethargy, dry mouth, and diaphoresis. Cardiovascular effects may depend on time post-ingestion and may present as hypotension or hypertension. The management of guanfacine overdose is largely supportive, with a focus on support of blood pressure. Overdose with ADHD medications can produce major morbidity, with many cases requiring intensive care medicine and prolonged hospital stays. However, fatalities are rare with appropriate care.
23757186	0	8	Overdose	Disease	MESH:D062787
23757186	22	62	attention-deficit hyperactivity disorder	Disease	MESH:D001289
23757186	101	109	toxicity	Disease	MESH:D064420
23757186	145	185	attention-deficit hyperactivity disorder	Disease	MESH:D001289
23757186	187	191	ADHD	Disease	MESH:D001289
23757186	308	324	ADHD medications	Disease	MESH:D001289
23757186	425	430	human	Species	9606
23757186	444	460	ADHD medications	Disease	MESH:D001289
23757186	562	566	ADHD	Disease	MESH:D001289
23757186	648	659	amphetamine	Chemical	MESH:D000661
23757186	661	676	methylphenidate	Chemical	MESH:D008774
23757186	682	691	modafinil	Chemical	MESH:D000077408
23757186	724	735	atomoxetine	Chemical	MESH:D000069445
23757186	737	747	guanfacine	Chemical	MESH:D016316
23757186	753	762	clonidine	Chemical	MESH:D003000
23757186	801	809	toxicity	Disease	MESH:D064420
23757186	816	824	overdose	Disease	MESH:D062787
23757186	830	846	ADHD medications	Disease	MESH:D001289
23757186	870	878	overdose	Disease	MESH:D062787
23757186	896	907	Amphetamine	Chemical	MESH:D000661
23757186	909	926	dextroamphetamine	Chemical	MESH:D003913
23757186	932	947	methylphenidate	Chemical	MESH:D008774
23757186	1021	1041	dopamine transporter	Gene	6531
23757186	1043	1046	DAT	Gene	6531
23757186	1089	1110	serotonin transporter	Gene	6532
23757186	1129	1137	toxicity	Disease	MESH:D064420
23757186	1186	1194	dopamine	Chemical	MESH:D004298
23757186	1196	1210	norepinephrine	Chemical	MESH:D009638
23757186	1216	1225	serotonin	Chemical	MESH:D012701
23757186	1276	1288	neurological	Disease	MESH:D009461
23757186	1421	1429	overdose	Disease	MESH:D062787
23757186	1435	1442	patient	Species	9606
23757186	1460	1469	mydriasis	Disease	MESH:D015878
23757186	1471	1477	tremor	Disease	MESH:D014202
23757186	1479	1488	agitation	Disease	MESH:D011595
23757186	1490	1503	hyperreflexia	Disease	MESH:D012021
23757186	1536	1550	hallucinations	Disease	MESH:D006212
23757186	1552	1560	delirium	Disease	MESH:D003693
23757186	1562	1569	anxiety	Disease	MESH:D001007
23757186	1571	1579	paranoia	Disease	MESH:D010259
23757186	1581	1599	movement disorders	Disease	MESH:D009069
23757186	1605	1613	seizures	Disease	MESH:D012640
23757186	1633	1644	amphetamine	Chemical	MESH:D000661
23757186	1646	1663	dextroamphetamine	Chemical	MESH:D003913
23757186	1669	1684	methylphenidate	Chemical	MESH:D008774
23757186	1685	1693	overdose	Disease	MESH:D062787
23757186	1800	1815	benzodiazepines	Chemical	MESH:D001569
23757186	1832	1841	agitation	Disease	MESH:D011595
23757186	1843	1851	delirium	Disease	MESH:D003693
23757186	1857	1875	movement disorders	Disease	MESH:D009069
23757186	1896	1911	benzodiazepines	Chemical	MESH:D001569
23757186	1966	1977	ziprasidone	Chemical	MESH:C092292
23757186	1981	1992	haloperidol	Chemical	MESH:D006220
23757186	2040	2055	dexmedetomidine	Chemical	MESH:D020927
23757186	2060	2068	propofol	Chemical	MESH:D015742
23757186	2070	2079	Modafinil	Chemical	MESH:D000077408
23757186	2120	2124	ADHD	Disease	MESH:D001289
23757186	2164	2168	ADHD	Disease	MESH:D001289
23757186	2312	2321	modafinil	Chemical	MESH:D000077408
23757186	2427	2435	dopamine	Chemical	MESH:D004298
23757186	2437	2451	norepinephrine	Chemical	MESH:D009638
23757186	2457	2466	serotonin	Chemical	MESH:D012701
23757186	2485	2493	Overdose	Disease	MESH:D062787
23757186	2499	2508	modafinil	Chemical	MESH:D000077408
23757186	2605	2617	neurological	Disease	MESH:D009461
23757186	2644	2651	anxiety	Disease	MESH:D001007
23757186	2653	2662	agitation	Disease	MESH:D011595
23757186	2664	2672	headache	Disease	MESH:D006261
23757186	2674	2683	dizziness	Disease	MESH:D004244
23757186	2685	2693	insomnia	Disease	MESH:D007319
23757186	2695	2702	tremors	Disease	MESH:D014202
23757186	2708	2716	dystonia	Disease	MESH:D004421
23757186	2736	2745	modafinil	Chemical	MESH:D000077408
23757186	2746	2754	overdose	Disease	MESH:D062787
23757186	2819	2830	dyskinesias	Disease	MESH:D004409
23757186	2851	2862	Atomoxetine	Chemical	MESH:D000069445
23757186	2890	2916	norepinephrine transporter	Gene	6530
23757186	2960	2968	overdose	Disease	MESH:D062787
23757186	2974	2985	atomoxetine	Chemical	MESH:D000069445
23757186	3053	3062	agitation	Disease	MESH:D011595
23757186	3064	3077	hyperactivity	Disease	MESH:D006948
23757186	3079	3087	GI upset	Disease	MESH:D005767
23757186	3089	3095	tremor	Disease	MESH:D014202
23757186	3097	3110	hyperreflexia	Disease	MESH:D012021
23757186	3112	3123	tachycardia	Disease	MESH:D013610
23757186	3124	3136	hypertension	Disease	MESH:D006973
23757186	3142	3149	seizure	Disease	MESH:D012640
23757186	3169	3180	atomoxetine	Chemical	MESH:D000069445
23757186	3181	3189	overdose	Disease	MESH:D062787
23757186	3254	3265	dyskinesias	Disease	MESH:D004409
23757186	3270	3278	seizures	Disease	MESH:D012640
23757186	3280	3289	Clonidine	Chemical	MESH:D003000
23757186	3305	3314	imidazole	Chemical	MESH:C029899
23757186	3442	3454	neurological	Disease	MESH:D009461
23757186	3527	3536	depressed	Disease	MESH:D003866
23757186	3548	3559	bradycardia	Disease	MESH:D001919
23757186	3565	3576	hypotension	Disease	MESH:D007022
23757186	3584	3593	clonidine	Chemical	MESH:D003000
23757186	3605	3617	hypertensive	Disease	MESH:D006973
23757186	3644	3656	hypertension	Disease	MESH:D006973
23757186	3678	3686	overdose	Disease	MESH:D062787
23757186	3716	3724	overdose	Disease	MESH:D062787
23757186	3728	3738	guanfacine	Chemical	MESH:D016316
23757186	3861	3869	lethargy	Disease	MESH:D053609
23757186	3871	3880	dry mouth	Disease	MESH:D014987
23757186	3975	3986	hypotension	Disease	MESH:D007022
23757186	3990	4002	hypertension	Disease	MESH:D006973
23757186	4022	4032	guanfacine	Chemical	MESH:D016316
23757186	4033	4041	overdose	Disease	MESH:D062787
23757186	4108	4116	Overdose	Disease	MESH:D062787
23757186	4122	4138	ADHD medications	Disease	MESH:D001289
23757186	4257	4267	fatalities	Disease	MESH:C565541
23757186	Negative_Correlation	MESH:D000661	MESH:D001289
23757186	Positive_Correlation	MESH:D000077408	MESH:D013610
23757186	Negative_Correlation	MESH:C092292	MESH:D003693
23757186	Positive_Correlation	MESH:D000077408	MESH:D005767
23757186	Association	MESH:D004244	6530
23757186	Association	MESH:C029899	MESH:D006973
23757186	Positive_Correlation	MESH:D008774	MESH:D009461
23757186	Association	MESH:C029899	MESH:D007319
23757186	Association	MESH:D003913	6532
23757186	Positive_Correlation	MESH:D000077408	MESH:D007022
23757186	Association	MESH:C565541	6530
23757186	Association	MESH:D007022	6530
23757186	Association	MESH:D000661	6531
23757186	Negative_Correlation	MESH:D015742	MESH:D009069
23757186	Association	MESH:D013610	6530
23757186	Association	MESH:D014987	6530
23757186	Positive_Correlation	MESH:D003913	MESH:D004244
23757186	Positive_Correlation	MESH:D008774	MESH:D001919
23757186	Positive_Correlation	MESH:D000077408	MESH:D004244
23757186	Positive_Correlation	MESH:D000077408	MESH:D009638
23757186	Positive_Correlation	MESH:D003913	MESH:D007022
23757186	Association	MESH:D003866	6530
23757186	Positive_Correlation	MESH:D016316	MESH:D007022
23757186	Association	MESH:C029899	MESH:D004409
23757186	Association	MESH:D000661	6532
23757186	Negative_Correlation	MESH:D015742	MESH:D003693
23757186	Association	MESH:C029899	MESH:D013610
23757186	Negative_Correlation	MESH:D001569	MESH:D011595
23757186	Negative_Correlation	MESH:D016316	MESH:D001289
23757186	Positive_Correlation	MESH:D003913	MESH:D001919
23757186	Association	MESH:D006973	6530
23757186	Negative_Correlation	MESH:D020927	MESH:D003693
23757186	Negative_Correlation	MESH:D000069445	MESH:D001289
23757186	Association	MESH:C029899	MESH:D053609
23757186	Positive_Correlation	MESH:D003913	MESH:D005767
23757186	Association	MESH:D005767	6530
23757186	Negative_Correlation	MESH:D006220	MESH:D011595
23757186	Negative_Correlation	MESH:D003000	MESH:D001289
23757186	Association	MESH:D008774	6532
23757186	Negative_Correlation	MESH:C092292	MESH:D011595
23757186	Negative_Correlation	MESH:D020927	MESH:D009069
23757186	Positive_Correlation	MESH:D000661	MESH:D001919
23757186	Negative_Correlation	MESH:D006220	MESH:D009069
23757186	Negative_Correlation	MESH:D020927	MESH:D011595
23757186	Association	MESH:C029899	MESH:D006948
23757186	Positive_Correlation	MESH:C029899	MESH:D007022
23757186	Negative_Correlation	MESH:D000077408	MESH:D001289
23757186	Association	MESH:C029899	MESH:D006261
23757186	Association	MESH:D006948	6530
23757186	Negative_Correlation	MESH:D001569	MESH:D008774
23757186	Association	MESH:D008774	6531
23757186	Positive_Correlation	MESH:D008774	MESH:D007022
23757186	Negative_Correlation	MESH:D001569	MESH:D062787
23757186	Negative_Correlation	MESH:D015742	MESH:D011595
23757186	Negative_Correlation	MESH:C092292	MESH:D009069
23757186	Association	MESH:D004409	6530
23757186	Positive_Correlation	MESH:D000661	MESH:D009461
23757186	Positive_Correlation	MESH:D003913	MESH:D013610
23757186	Positive_Correlation	MESH:D000077408	MESH:D006261
23757186	Association	MESH:C029899	6530
23757186	Positive_Correlation	MESH:D000077408	MESH:D004298
23757186	Positive_Correlation	MESH:D000077408	MESH:D001919
23757186	Association	MESH:D001919	6530
23757186	Association	MESH:D003913	6531
23757186	Positive_Correlation	MESH:D000661	MESH:D007022
23757186	Association	MESH:D004421	6530
23757186	Negative_Correlation	MESH:D008774	MESH:D001289
23757186	Association	MESH:D007319	6530
23757186	Negative_Correlation	MESH:D006220	MESH:D003693
23757186	Association	MESH:C029899	MESH:D005767
23757186	Association	MESH:D006261	6530
23757186	Association	MESH:D053609	6530
23757186	Association	MESH:C029899	MESH:D004244

